PrintFriendly

Print Friendly, PDF & Email

MASAC Recommendation Concerning Reimbursement for Recombinant Clotting Factor Concentrates

Date: 
November 9, 2003
ID: 
153
AttachmentSize
PDF icon MASAC Document248.41 KB
  • There are now available several different recombinant factor products for the treatment of hemophilia. There are specific considerations in prescribing a product for any individual patient.

    Therefore MASAC recommends that insurance companies and other third-party payers such as Medicaid, Medicare, CMS, etc. cover whichever recombinant factor product is prescribed by the patient’s treating physician.